Reuters Television Report features NanoLogix Biotechnology and University of Texas Health Science Center Clinical Trial
February 17 2011 - 5:00AM
Business Wire
NanoLogix (PINK SHEETS: NNLX), an innovator in the accelerated
detection and identification of live-cell microorganisms, announced
today Reuters Television has featured the NanoLogix rapid
diagnostic technology in its global business coverage.
The video can be viewed here:
http://www.reuters.com/news/video/story?videoId=187843449&videoChannel=5
Produced by Rob Muir, the report from Reuters features an
interview with NanoLogix CEO Bret Barnhizer while the company was
exhibiting at the American Society for Microbiology BioDefense and
Emerging Diseases Research Meeting and Exhibition held in
Washington, DC (February 7-9, 2011). The report includes an
additional interview with Dr. Jonathan Faro of the University of
Texas Health Science Center- Houston. Dr. Faro is currently leading
a 300 patient trial utilizing NanoLogix BNP/BNF/Quick-Test
technologies for rapid detection of Group B Streptococcus
(GBS).
Group B Strep is one of the leading health threats for newborns.
Current methods for detection and identification take 48 to 72+
hours for results. The new technology from NanoLogix enables
detection, identification, and determination of antibiotic
sensitivity in 6 hours or less.
NanoLogix will return to Washington DC April 19-21, 2011 for the
Food Safety Summit, where the company's technology will be on
exhibit. Additional information about the event can be found at
http://www.foodsafetysummit.com.
Joining NanoLogix at the Food Safety Summit will be John Tracy,
who now serves the company in the position of General Operations
Manager. Mr. Tracy brings 30 years of international technology
management experience to NanoLogix from his career with both IBM
and EMC.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing.
Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and
antibiotic sensitivity. For more information visit
www.nanologix.com.
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jul 2023 to Jul 2024